ConductScience.org, home

Paper2931964

The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.

De Cree J and 4 others. Agents Actions, 1985. Cited by 24 papers, by iCite.

Cite this record

ConductScience Library. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases. Papers, record 2931964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2931964

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
PubMed
Journal
Agents Actions
PubMed
Year
1985
PubMed
Publication types
Clinical Trial, Controlled Clinical Trial, Journal Article
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
1.64
iCite
Revised in PubMed
2019-08-24
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1De Cree JJ
2Leempoels JJ
3Demoen BB
4Roels VV
5Verhaegen HH

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
PiperidinesMajor topic
Platelet AggregationMajor topic
SerotoninMajor topic
Aged
Arterial Occlusive Diseases
Double-Blind Method
Female
Humans
Ketanserin
Male
Middle Aged
Myocardial Infarction
Placebos
beta-Thromboglobulin

Source PubMed

Download CSV of topics

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15447960A biphasic response of platelets to serotonin.Scand J Haematol1970https://conductscience.org/library/papers/5447960PubMed
26113280Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.J Pharmacol Exp Ther1981https://conductscience.org/library/papers/6113280PubMed
36158764beta-Thromboglobulin--a specific marker of in-vivo platelet release reaction.Thromb Haemost1980https://conductscience.org/library/papers/6158764PubMed
46183969Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction.Am J Cardiol1982https://conductscience.org/library/papers/6183969PubMed
574664Elevated beta-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy.Lancet1978https://conductscience.org/library/papers/74664PubMed
67350460Platelet activation during exercise-induced myocardial ischemia.N Engl J Med1980https://conductscience.org/library/papers/7350460PubMed
77148644In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction.Am Heart J1982https://conductscience.org/library/papers/7148644PubMed
86193378Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia.Lancet1983https://conductscience.org/library/papers/6193378PubMed
96710435The involvement of 5-HT2-receptor sites in the activation of cat platelets.Thromb Res1984https://conductscience.org/library/papers/6710435PubMed
10621432Elevation of platelet factor four in acute myocardial infarction: measurement by radioimmunoassay.J Lab Clin Med1978https://conductscience.org/library/papers/621432PubMed
116261070Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.Life Sci1981https://conductscience.org/library/papers/6261070PubMed
124744691Platelet abnormalities in ischemic heart disease.Am J Cardiol1973https://conductscience.org/library/papers/4744691PubMed
136612677Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.Thromb Res1983https://conductscience.org/library/papers/6612677PubMed
147011110The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R 41 468) in elderly patients.Angiology1981https://conductscience.org/library/papers/7011110PubMed
156800533Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.Br Med J (Clin Res Ed)1982https://conductscience.org/library/papers/6800533PubMed
164696737Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemic heart disease.Atherosclerosis1973https://conductscience.org/library/papers/4696737PubMed
176817452Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin.Thromb Res1982https://conductscience.org/library/papers/6817452PubMed
187455982Platelet aggregates in ischemic heart disease.Thromb Haemost1980https://conductscience.org/library/papers/7455982PubMed
194512589Influence of lysolecithin on platelet aggregation initiated by 5-hydroxytryptamine.Nat New Biol1973https://conductscience.org/library/papers/4512589PubMed
206854135Plasma platelet products and exercise-induced myocardial ischemia.J Lab Clin Med1983https://conductscience.org/library/papers/6854135PubMed

See all 25 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
8453957Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.Eur J Clin Pharmacol1993https://conductscience.org/library/papers/8453957PubMed
3240733Hyperreactivity of platelets to serotonin (5-hydroxytryptamine) in patients with cardiovascular diseases. Influence of ketanserin, a serotonin S2-receptor antagonist.Drugs1988https://conductscience.org/library/papers/3240733PubMed
2939698Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.Agents Actions1986https://conductscience.org/library/papers/2939698PubMed
2467792Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin.Drugs1988https://conductscience.org/library/papers/2467792PubMed
2285642Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension.Cardiovasc Drugs Ther1990https://conductscience.org/library/papers/2285642PubMed
2079001Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.Drugs1990https://conductscience.org/library/papers/2079001PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
HTR2A3356PubTator's text mininghttps://conductscience.org/library/genes/3356NCBI Gene
PPBP5473PubTator's text mininghttps://conductscience.org/library/genes/5473NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2931964

GET https://conductscience.org/api/papers/v1/2931964/references?page=2